 |
| |
 | | Guidelines | |
| | American Diabetes Association, 2007 | | | Standards of medical care in diabetes—2007 | | | Testing for diabetes should be considered in all individuals aged 45 years or older, particularly in those with a BMI 25 kg/m2, and, if normal, should be repeated at 3-year intervals. Testing should be considered at a younger age or be carried out more frequently in individuals who are overweight (BMI 25 kg/m2) and have the following additional risk factors: habitual physical inactivity; first-degree relative with diabetes; member of a high-risk ethnic population (e.g., black, Latino, Native American, Asian American, Pacific Islander); delivery of a baby weighing more than 9 lbs. or diagnosis of gestational diabetes; hypertension (BP 140/90 mm Hg); HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or triglyceride level >250 mg/dL (2.82 mmol/L); polycystic ovary syndrome; impaired glucose tolerance or impaired fasting glucose on previous testing; other clinical conditions associated with insulin resistance (e.g., polycystic ovary syndrome or acanthosis nigricans); history of vascular disease. | | American Diabetes Association, 2004 | | | Screening for type 2 diabetes | | | All persons should be screened using an FBG test at 3-year intervals beginning at age 45; testing should be considered at an earlier age or be carried out more frequently in those who are overweight if additional diabetes risk factors are present. | | Annals of Internal Medicine, 2003 | | | Screening for type 2 diabetes mellitus in adults: recommendations and rationale | | | The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routinely screening asymptomatic adults for type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose. This is a grade I recommendation. | | Canadian Diabetes Association, 2003 | | | Clinical practice guidelines for the prevention and management of diabetes in Canada: Screening and prevention | | | Screening for diabetes using an FBG test should be performed every 3 years in persons aged 40 years or older, and more frequent or earlier testing should be done in those with risk factors for diabetes. | | Canadian Task Force on Preventive Medicine, 1994 | | | Screening for diabetes mellitus in the non-pregnant adult | | | The CTF found fair evidence to exclude diabetes screening of the nonpregnant population from the periodic health examination. | | U.S. Preventive Services Task Force, 2008 | | | Screening for type 2 diabetes mellitus in adults | | | The USPSTF recommends screening for type 2 diabetes in asymptomatic adults with sustained BP >135/80 mm Hg (B recommendation) and concludes that the current evidence is insufficient to determine the balance of benefits and harms of screening for type 2 diabetes in asymptomatic adults with BP 135/80 mm Hg. | | | FAQs |
|
| Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Screening for Type 2 Diabetes
